David Gallo - Terrence Donnelly Center for Cellular and Biomolecular Research, University of Toronto

基本信息

浏览量：9

职业迁徙

个人简介

David Gallo currently works at the Department of Biochemistry, University of Toronto. David does research in Molecular Biology. Their most recent publication is 'Rad5 Recruits Error-Prone DNA Polymerases for Mutagenic Repair of ssDNA Gaps on Undamaged Templates'.

研究兴趣

论文共 32 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR

Haineng Xu,Erin George,David Gallo,Sergey Medvedev, Xiaolei Wang,Rosie Kryczka,Marc L Hyer,Jimmy Fourtounis,Rino Stocco,Elia Aguado-Fraile,Adam Petrone,Shou Yun Yin, Ariya Shiwram,Matthew Anderson,Hyoung Kim,Fang Liu,C Gary Marshall,Fiona Simpkins

Research square (2024)

引用0浏览0WOS引用

Synthetic Lethal Strategies for the Development of Cancer Therapeutics

Natalie Y L Ngoi,David Gallo,Carlos Torrado, Mirella Nardo,Daniel Durocher,Timothy A Yap

Nature reviews Clinical oncology (2024)

引用0浏览0WOSNATURE引用

Supplementary Figures from Haploinsufficiency of an RB–E2F1–Condensin II Complex Leads to Aberrant Replication and Aneuploidy

Courtney H. Coschi,Charles A. Ishak,David Gallo,Aren Marshall,Srikanth Talluri, Jianxin Wang,Matthew J. Cecchini,Alison L. Martens, Vanessa Percy,Ian Welch,Paul C. Boutros,Grant W. Brown,Frederick A. Dick

crossref（2023）

引用0浏览0引用

Abstract A023: Preclinical Development of PKMYT1 and WEE1 Inhibitor Combinations

David Gallo,Fenil Shah,Rino Stocco,Prasamit Baruah,Jimmy Fourtounis,Rosie Kryczka,Marc L Hyer,Anne Roulston,C Gary Marshall,Michal Zimmermann,Stephen Morris,Michael Zinda

Molecular Cancer Therapeuticsno. 12_Supplement (2023)

引用0浏览0引用

Abstract B057: Preclinical Development of PKMYT1 and ATR Inhibitor Combinations

David Gallo,Marc L. Hyer,Giovanni Martino, Adam Pertrone,Elia Aguado-Fraile,Rosie Kryczka,Jimmy Fourtounis,Rino Stocco,Stephen J. Morris,C. Gary Marshall,Anne Roulston,Michael Zinda,Michal Zimmermann

Molecular Cancer Therapeuticsno. 12_Supplement (2023)

引用0浏览0引用

Abstract C163: KRAS Alterations Combined with TP53 Mutations As Novel Synthetic Lethal Genomic Lesions for PKMYT1 Inhibition

Marc L. Hyer,Jimmy Fourtounis,David Gallo,Vivek Bhaskaran,Rino Stocco,Rosie Kryczka, Sai Save, Helen Burston,Olivier Nicolas,Stephen Morris,Anne Roulston,Jordan T. F. Young,Michal Zimmermann,C. Gary Marshall,Artur Veloso,Elia Aguado-Fraile

Molecular Cancer Therapeuticsno. 12_Supplement (2023)

引用0浏览0引用

CDK12 Loss Leads to Replication Stress and Sensitivity to Combinations of the ATR Inhibitor Camonsertib (RP-3500) with PARP Inhibitors

J. Setton,D. Gallo,D. Glodzik, B. Kaiser, S. Braverman, T. Ubhi, S. Fournier,P. Selenica, N. Laterreur,A. Roulston, G. Brown, S. Morris,J. Reis-Filho, M. Zimmermann

European Journal of Cancer（2022）

引用0浏览0引用

The PKMYT1 Inhibitor RP-6306 Has Synergistic Efficacy with Carboplatin in CCNE1 Amplified Tumor Models

J. Fourtounis,D. Gallo,A. Roulston,R. Stocco, G. Martino, S. Fournier, E. Aguado, R. Kryczka,V. Bhaskaran, S. Morris,C. G. Marshall

European Journal of Cancer（2022）

引用0浏览0引用

RP-6306, a novel PKMYT1 inhibitor, demonstrates synthetic lethality as monotherapy and in combination with gemcitabine in CCNE1 amplified cancer cells

Jimmy Fourtounis, John Martino,Rino Stocco,Prasamit Baruah,Nicole Duffy,David Gallo,Sarah Fournier, JingJing Li,Li Li,Elia Aguado,Adam Petrone,Anne Roulston,Yael Mamane,Stephen Morris,Janek Szychowski,Robert Papp,Mike Zinda,C. Gary Marshall

CANCER RESEARCH（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn